Clinical trials in the new millennium

Area of Science:

• Clinical Trials Methodology
• Genomic Medicine
• Global Health Ethics

Background:

• Randomized clinical trials (RCTs) have been fundamental in evaluating pharmacologic and biologic agents for over 50 years.
• Advances in statistical methods and information technology have expanded the reach and efficiency of clinical trials globally.
• Academia, industry, and government have collaborated to achieve significant milestones in RCTs.

Purpose of the Study:

• To discuss the evolution and future challenges of randomized clinical trials.
• To explore the impact of the post-genomics era on clinical trial design and patient selection.
• To examine the changing landscape of regulatory approval for medical devices, procedures, and alternative medicines.

Main Methods:

• Review of the historical development and achievements of randomized clinical trials.
• Discussion of emerging trends including genomics, personalized medicine, and novel therapeutic areas.
• Consideration of ethical and scientific challenges in international clinical trials, particularly in resource-limited settings.

Main Results:

• The post-genomics era offers opportunities for more precise disease mechanism identification and targeted treatment development.
• Increased efficiency in clinical trials can be achieved through better patient stratification.
• Areas like medical devices, procedures, and alternative medicines require enhanced evaluation using RCT methodologies.

Conclusions:

• The future of clinical trials is dynamic, with significant potential for advancing medicine and healthcare through innovative approaches.
• Ethical considerations are paramount when conducting international clinical trials, ensuring patient welfare and avoiding exploitation.
• The continued application and adaptation of RCT methodology are essential for evidence-based medical progress.